Neurogene is a developer of genetic medicines intended to improve patient outcomes for neurological disorders.
Neurogene has raised $125.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in July 2026.
Neurogene's investors include BlackRock, Cormorant Asset Management, Janus Henderson Investors, Samsara BioCapital, Redmile Group.
Neurogene is headquartered in New York, United States.
Neurogene is a developer of genetic medicines intended to improve patient outcomes for neurological disorders.
Neurogene is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Neurogene — Funding & Investors." VCBacked, July 1, 2026, https://www.vcbacked.co/company/neurogene. Accessed September 29, 2026.
VCBacked. (2026). Neurogene — Funding & Investors. Retrieved September 29, 2026, from https://www.vcbacked.co/company/neurogene
{{cite web |title=Neurogene — Funding & Investors |url=https://www.vcbacked.co/company/neurogene |website=VCBacked |access-date=September 29, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated